Aduro Biotech (ADRO) to Acquire BioNovion in EUR 29M Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Aduro Biotech Enters Into Definitive Agreement to Acquire Premier Antibody Portfolio and Engineering Capabilities Through Purchase of BioNovion
September 24, 2015 4:00 PM EDTAduro's innovative technology portfolio broadens with BioNovion's well-established antibody discovery and optimization capabilities  Aduro's preclinical pipeline expands to include immune checkpoint inhibitors and other monoclonal antibody candidates with unique specificity  Terms include initial payment of 14.5 million Euro in cash and 14.5 million Euro in Aduro stock, plus future contingent payments  Aduro will host a conference call today at 1:30 pm Pacific to discuss the transaction
BERKELEY, Calif. and OSS, The Netherlands, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO) and BioNovion Holding B.V. announced today that they... More
